David B. Solit

发表

Abstract 2482: A portable bioinformatics pipeline for the FDA authorized IMPACT DNAseq assay

Nikhil Kumar, Cyriac Kandoth, Feng Liu, 2019, Bioinformatics, Convergence Science, and Systems Biology.

Abstract 5351: Retrospective analysis of cancer exomes with Roslin, a portable and reproducible workflow infrastructure

Nikhil Kumar, Cyriac Kandoth, Shweta S. Chavan, 2018 .

Perturbation Biology: Inferring Signaling Networks in Cellular Systems

Weiqing Wang, Chris Sander, Riccardo Zecchina, 2013, PLoS Comput. Biol..

Abstract 682: Drug repurposing engine fueled by diverse drug similarity data

Coryandar Gilvary, Jamal Elkhader, Neel Madhukar, 2019 .

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Sarat Chandarlapaty, Neal Rosen, David B. Solit, 2008, Clinical Cancer Research.

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor

Obi L. Griffith, Malachi Griffith, Benjamin J. Ainscough, 2014, Nature.

BRAF mutation predicts sensitivity to MEK inhibition

Todd R. Golub, Gad Getz, Andrea Basso, 2006, Nature.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Tom Misteli, Mark C. Kelley, Neal Rosen, 2011, Nature.

Comparison of genomic alterations in bladder urothelial tumors with and without telomerase reverse transcriptase promoter mutation using a next-generation sequencing assay.

Ahmet Zehir, Michael F. Berger, David B. Solit, 2017 .

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer

Cyriac Kandoth, Mitchell C. Benson, Jonathan A. Coleman, 2018, Cell.

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

Qiang Li, Joaquim Bellmunt, Nadeem Riaz, 2018, Clinical Cancer Research.